Editorial: Challenges of pharmacoeconomics in global health arena-Contemporary momentum in the early 2020s

Mihajlo Jakovljevic; Nick Verhaeghe; Kyriakos Souliotis; Kristijan Krstic

doi:10.3389/fpubh.2023.1189671

Editorial: Challenges of pharmacoeconomics in global health arena-Contemporary momentum in the early 2020s

Front Public Health. 2023 Apr 13:11:1189671. doi: 10.3389/fpubh.2023.1189671. eCollection 2023.

Authors

Mihajlo Jakovljevic^{1

2

3}, Nick Verhaeghe^{4

5}, Kyriakos Souliotis⁶, Kristijan Krstic⁷

Affiliations

¹ Institute of Advanced Manufacturing Technologies, Peter the Great St. Petersburg Polytechnic University, Saint Petersburg, Russia.
² Institute of Comparative Economic Studies, Hosei University, Tokyo, Japan.
³ Department of Global Health Economics and Policy, University of Kragujevac, Kragujevac, Serbia.
⁴ Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Interuniversity Centre for Health Economics Research, Ghent University, Ghent, Belgium.
⁵ Interuniversity Centre for Health Economics Research, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium.
⁶ Faculty of Social and Political Sciences, University of Peloponnese, Corinth, Greece.
⁷ Department of Physical Medicine and Rehabilitation, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.

No abstract available

Keywords: costs; drugs; global; medicines; pharmaceutical expenditure; pharmaceutical policy; pharmacoeconomics; reimbursement.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Drug Costs
Economics, Pharmaceutical*
Global Health*

Grants and funding

Serbian part of this contribution has been co-financed through Grant OI 175014 of the Ministry of Education Science and Technological Development of the Republic of Serbia.